Biomark Diagnostics Logo
CA09073K1084
A12EKB
BUX.CN

Biomark Diagnostics

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Biomark Diagnostics had revenue of €4.32k and net profit of -€224.67k
(EUR) June 2026
YoY
Revenue 4.32k 82.22%
Gross profit 4.32k 82.22%
Net profit -224.67k 13.39%
EBITDA -205.22k 7.41%

Fundamentals

Metric Value
Market capitalization
€31.21m
Number of shares
106.48m
52-week high/low
€0.46 - €0.21
Dividends No
Beta
-0.31
P/E ratio
-31.11
PEG ratio
-0.90
P/B ratio
78.20
P/S ratio
1,608.56

Company profile

BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.

Name
Biomark Diagnostics
CEO
Rashid Ahmed Maula Bux
Headquarters Richmond, bc
Canada
Website
IPO
03/11/2014
Employees 9

Ticker symbols

Exchange Symbol
Cnq
BUX.CN
Pnk
BMKDF
Frankfurt
20B.F
🍪

Parqet  uses cookies. Learn more